Basilea Pharmaceutica AGBasilea Pharmaceutica AGBasilea Pharmaceutica AG

Basilea Pharmaceutica AG

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪571.87 M‬CHF
6.00CHF
‪77.59 M‬CHF
‪208.54 M‬CHF
‪11.31 M‬
Beta (1Y)
0.99
Employees (FY)
164
Change (1Y)
+17 +11.56%
Revenue / Employee (1Y)
‪1.27 M‬CHF
Net income / Employee (1Y)
‪473.13 K‬CHF

About Basilea Pharmaceutica AG


CEO
David Veitch
Headquarters
Allschwil
Founded
2000
ISIN
CH0011432447
FIGI
BBG000BWPHB9
Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. Its products include antifungals and antibiotics. The company was founded on October 17, 2000, and is headquartered in Allschwil, Switzerland.

Check out other big names from the same industry as BSLN.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of BSLN is 46.90 CHF — it has decreased by −0.96% in the past 24 hours. Watch Basilea Pharmaceutica AG stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on SIX exchange Basilea Pharmaceutica AG stocks are traded under the ticker BSLN.
BSLN stock has risen by 1.42% compared to the previous week, the month change is a −1.59% fall, over the last year Basilea Pharmaceutica AG has showed a 0.43% increase.
We've gathered analysts' opinions on Basilea Pharmaceutica AG future price: according to them, BSLN price has a max estimate of 105.00 CHF and a min estimate of 55.70 CHF. Watch BSLN chart and read a more detailed Basilea Pharmaceutica AG stock forecast: see what analysts think of Basilea Pharmaceutica AG and suggest that you do with its stocks.
BSLN reached its all-time high on Mar 30, 2007 with the price of 284.75 CHF, and its all-time low was 28.55 CHF and was reached on Sep 15, 2011. View more price dynamics on BSLN chart.
See other stocks reaching their highest and lowest prices.
BSLN stock is 1.62% volatile and has beta coefficient of 0.99. Track Basilea Pharmaceutica AG stock price on the chart and check out the list of the most volatile stocks — is Basilea Pharmaceutica AG there?
Today Basilea Pharmaceutica AG has the market capitalization of ‪576.90 M‬, it has increased by 0.22% over the last week.
Yes, you can track Basilea Pharmaceutica AG financials in yearly and quarterly reports right on TradingView.
Basilea Pharmaceutica AG is going to release the next earnings report on Feb 17, 2026. Keep track of upcoming events with our Earnings Calendar.
BSLN earnings for the last half-year are 1.26 CHF per share, whereas the estimation was 2.03 CHF, resulting in a −37.93% surprise. The estimated earnings for the next half-year are 1.73 CHF per share. See more details about Basilea Pharmaceutica AG earnings.
Basilea Pharmaceutica AG revenue for the last half-year amounts to ‪104.00 M‬ CHF, despite the estimated figure of ‪98.20 M‬ CHF. In the next half-year revenue is expected to reach ‪121.00 M‬ CHF.
BSLN net income for the last half-year is ‪15.80 M‬ CHF, while the previous report showed ‪56.86 M‬ CHF of net income which accounts for −72.21% change. Track more Basilea Pharmaceutica AG financial stats to get the full picture.
No, BSLN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 23, 2025, the company has 164 employees. See our rating of the largest employees — is Basilea Pharmaceutica AG on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Basilea Pharmaceutica AG EBITDA is ‪79.63 M‬ CHF, and current EBITDA margin is 31.03%. See more stats in Basilea Pharmaceutica AG financial statements.
Like other stocks, BSLN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Basilea Pharmaceutica AG stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Basilea Pharmaceutica AG technincal analysis shows the neutral today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Basilea Pharmaceutica AG stock shows the buy signal. See more of Basilea Pharmaceutica AG technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.